Abstract: Described herein are substituted benzenesulfonylureas and -thioureas of the formula (I): ##STR1## useful in treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrythmia. The compounds of formula (I) can be used as antiarrythmics and are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.

Abstract: Substituted benzenesulfonylureas and -thioureas--processes for their preparation and their use as pharmaceuticalsBenzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro)(mercapto)alk(oxy)yl, E is O or S; Y is --?CR(3).sub.2 !.sub.n --, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.

Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them.Substituted benzenesulfonylureas and -thioureas 1 ##STR1## exhibit effects on the cardiovascular system.

Abstract: Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit outstanding effects on the cardiovascular system.

Abstract: This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation, and uses of the pharmaceutical products based on these compounds. The substituted benzenesulfonylureas and -thioureas are of the formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 E, and y are as defined in the specification. The compounds of formula I have antiarrhythmic activity.

Abstract: Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and pharmaceutical preparations containing them.Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.

Abstract: Benzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro) (mercapto) alk (oxy) yl, E is O or S; Y is --[CR(3).sub.2 ]n-, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO.sub.2 or alk(yl)oxy, are described.The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.

Abstract: There are described amino-substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## The compounds I are used for the treatment of cardiac arrhythmias and for the prevention of sudden heart death caused by arrhythmias and can therefore be used as antiarrhythmics. They are particularly suitable for those cases in which arrhythmias are a result of constriction of a coronary vessel, such as in angina pectoris or in acute cardiac infarct.

Abstract: A process for the preparation of alkylhalogenosilanes by reaction of silicon with an alkyl halide in the presence of a copper catalyst and promoter substances, the improvement wherein gaseous phosphorus compounds are admixed, as promotor substances, with the stream of alkyl halide.

Abstract: Compounds I ##STR1## in which R(1) and R(4) equal H, alkyl, alkoxy, Hal, CF.sub.3, NO.sub.2, OH, acetamido or amino;R(2) equals H, alk(en)yl or phenylalkyl (optionally substituted);R(3) equals H, (cyclo)alk(en)yl-(alkyl), phenyl or phenylalkyl (optionally substituted);A equal CHOH, CO, CH.dbd.CH, C.tbd.C, CH.sub.2, O or S;m equals 1 or 2;n equals 1 to 3;p equals 0 to 4;R(5) equals some amino groups, and their salts, exhibit excellent calcium-antagonistic activity.Processes for their preparation are described.

Abstract: Calcium antagonists of the formula ##STR1## with R(1), R(2), R(3) and R(4) being, inter alia, H, alkyl, alkoxy, halogen, in some cases phenyl; m being 1-4; n being 0-3; X being CH.sub.2, O, S, CO, CHOH or CR.sub.2, and R(5) being various groups containing nitrogen atoms, are described.They are obtained by reaction of compounds II which are likewise new and which contain in place of R(5) a leaving group Y (Cl, Br, I) with the appropriate (cyclic) amino compound.Another synthesis comprises reaction of the appropriate indollinone derivative IV which has a non-etherified hydroxyl group with a side chain which contains a terminal leaving group Z (Cl, Br, I) in the presence of a base.Furthermore, indolinone derivatives VI with an ether side chain with a terminal epoxide group can be reacted with (cyclic) amines to give compounds I.

Abstract: Compounds I are described ##STR1## with R.sup.1 equal to (cyclo)alk(en)yl or ##STR2## R.sup.2 /R.sup.3 equal to phenyl or phenylalkyl, A equal to ##STR3## m equal to 2-4, and n equal to 1-4.Compounds I and their salts are calcium antagonists.

Abstract: A compound I ##STR1## in which R.sup.1 is cycloalkyl, alkenyl, cycloalkenyl, phenyl, ##STR2## whereJ, L, M, and E are methine or nitrogen and J', L', M', and E' are methylene, carbonyl or imino;R.sup.2 is phenyl or phenylalkyl;a is various amine radicals;m is 2, 3 or 4; andn is 1, 2, 3, or 4 is described; salts of these compounds I are also described. Compounds I and the salts are calcium antagonists.

Abstract: Calcium antagonists of the formula ##STR1## with R(1), R(2), R(3) and R(4) being, inter alia, H, alkyl, alkoxy, halogen, in some cases phenyl; m being 1-4; n being 0-3; X being CH.sub.2, O, S, CO, CHOH or CR.sub.2, and R(5) being various groups containing nitrogen atoms, are described.They are obtained by reaction of compounds II which are likewise new and which contain in place of R(5) a leaving group Y (Cl, Br, I) with the appropriate (cyclic) amino compound.Another synthesis comprises reaction of the appropriate indolinone derivative IV which has a non-etherified hydroxyl group with a side chain which contains a terminal leaving group Z (Cl, Br, I) in the presence of a base.Furthermore, indolinone derivatives VI with an ether side chain with a terminal epoxide group can be reacted with (cyclic) amines to give compounds I.

Abstract: Compounds of the formula I ##STR1## where R(1), R(2), R(3), R(4) and R(5) are, inter alia, hydrogen and alkyl, m is 1-4, n is 0 or 1, p is 0-4 and R(6) is identical or different dialkylamine derivatives, and salts thereof, have a calcium-antagonistic action. They are obtained by reacting corresponding amines with a compound II which carries, on the side chain, a leaving group which can be displaced nucleophilically, or from a hydroxyphenyl-dihydroquinolin-2-one compound by reaction with a corresponding side chain compound which has a leaving group which can be displaced nucleophilically.

Abstract: Isoquinoline-4-carboxylic acid derivatives of the formula I ##STR1## in which m, n, R.sup.1, R.sup.2, R.sup.3, A and X have the meansings indicated, and physiologically acceptable acid addition salts thereof, a process for their preparation, pharmaceutical formulations based on these compounds and the use thereof as antiarrythmic agents.

Abstract: Benzothiazine derivatives of the formula I ##STR1## with (R(1), R(1)', R(1)", R(4) and R(4)' equal to hydrogen, alkyl, alkoxy, halogen, nitro, hydroxyl, acetamido or amino; R(2) equal to hydrogen, alkyl, alkenyl, phenyl; R(3) equal to hydrogen, alkyl, alkenyl, phenyl; R(5) equal to hydrogen or (C.sub.1 -C.sub.

Abstract: New isoquinoline derivatives of the general formula ##STR1## and their physiologically acceptable salts, which exert pharmacological actions on the central nervous system and the heart circulation system, a process for the preparation of these compounds, medicaments containing them, and their use as neuroleptic, antihypertonic and antiarrhythmic agents, are described.

Abstract: The invention relates to a laser rotation rate sensor wherein two light beams counterrotate in a polygon equipped with reflectors at its corners, a signal being derived from their frequency difference in dependence on the rate of rotation. The rotation rate sensor comprises a reflector designed and operated as a magneto-optic element for the suppression of lock-in and including a prism whose base boundary face is disposed adjacent a layer of a gyrotropic material, the reflector being designed in such a manner that total reflection occurs. In the laser rotation rate sensor, the index of refraction of the gyrotropic material is approximately equal to or greater than that of the prism; a further layer of a dielectric material is disposed adjacent the gyrotropic layer, which further layer has a smaller index of refraction than the prism material and the material of the gyrotropic layer, in such a manner that total reflection occurs at the interface between the layer of gyrotropic material and the further layer.

Abstract: The invention relates to a laser rotation rate sensor wherein two light beams counterrotate in a polygon equipped with reflectors at its corners, a signal depending on the rate of rotation being derived from the frequency difference. One of the reflectors employed is designed as a magneto-optic element so as to suppress lock-in. This reflector includes a prism whose base boundary face is provided with a layer of a material having a lower index of refraction than the prism material. At least one of these materials is a gyrotropic material. Almost no reflection occurs when light enters the prism at the two lateral faces due to adherence to the Brewster condition. Further, the angle of incidence of the beams on the interface with the layer having a lower index of refraction than the prism material is so large that total reflection occurs.